8-K Announcements
6Material company update
Mar 19, 2026·SEC
Material company update
Feb 10, 2026·SEC
Material company update
Dec 9, 2025·SEC
CVS Health Corporation(CVS)Earnings, Financials & Key Ratios
CVS•NYSE•Insurance & Managed Care
$80.69
$102.56B mkt cap·58.1× P/E·Price updated May 6, 2026
AboutCVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Its Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail-order, mail-order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The company's Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. As of December 31, 2021, it operated approximately 9,900 retail locations and 1,200 MinuteClinic locations, as well as online retail pharmacy websites, LTC pharmacies, and onsite pharmacies. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.Show more
- Revenue$402.07B+7.8%
- Combined Ratio97.42%-0.3%
- Net Income$1.77B-61.7%
- Return on Equity2.34%-61.4%
- Medical Cost Ratio86.23%
- Operating Margin2.58%+13.1%
- Net Margin0.44%-64.5%
- ROA0.69%-62.5%
- Equity / Assets28.87%-3.5%
- Book Value per Share59.31-1.2%
- Tangible BV/Share-28.01+17.5%
- Debt/Equity1.24+13.4%
CVS Key Insights
CVS Health Corporation (CVS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Healthy dividend yield of 3.3%
- ✓Trading at only 1.4x book value
✗Weaknesses
- ✗Profits declining 24.4% over 5 years
- ✗High loss ratio of 86.2%
- ✗Dividend payout exceeds 100% of earnings
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CVS Price & Volume
CVS Health Corporation (CVS) stock price & volume — 10-year historical chart
Loading chart...
CVS Growth Metrics
CVS Health Corporation (CVS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years10.12%
5 Years8.39%
3 Years7.63%
TTM7.85%
Profit CAGR
10 Years-10.29%
5 Years-24.44%
3 Years-25.7%
TTM-61.68%
EPS CAGR
10 Years-11.34%
5 Years-23.94%
3 Years-24.73%
TTM-62.29%
Return on Capital
10 Years8.12%
5 Years6.47%
3 Years6.49%
Last Year6.09%
CVS Recent Earnings
CVS Health Corporation (CVS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 10/12 qtrs (83%)
Q1 2026Latest
Feb 10, 2026EPS
$1.09
Est $1.00
+9.0%
Revenue
$105.7B
Est $103.7B
+1.9%
Q4 2025
Oct 29, 2025EPS
$1.60
Est $1.37
+16.8%
Revenue
$102.9B
Est $98.8B
+4.1%
Q3 2025
Jul 31, 2025EPS
$1.81
Est $1.46
+24.0%
Revenue
$98.9B
Est $94.5B
+4.6%
Q2 2025
May 1, 2025EPS
$2.25
Est $1.70
+32.4%
Revenue
$94.6B
Est $93.7B
+1.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 10, 2026 | $1.09vs $1.00+9.0% | $105.7Bvs $103.7B+1.9% |
| Q4 2025 | Oct 29, 2025 | $1.60vs $1.37+16.8% | $102.9Bvs $98.8B+4.1% |
| Q3 2025 | Jul 31, 2025 | $1.81vs $1.46+24.0% | $98.9Bvs $94.5B+4.6% |
| Q2 2025 | May 1, 2025 | $2.25vs $1.70+32.4% | $94.6Bvs $93.7B+1.0% |
Based on last 12 quarters of dataView full earnings history →
CVS Peer Comparison
CVS Health Corporation (CVS) competitors in Vertically Integrated Payer-PBM Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 UNH | 330.28B | 363.87 | 27.50 | 11.81% | 2.68% | 11.54% | 4.87% | 0.77 |
 CI | 72.68B | 275.66 | 12.43 | 11.26% | 2.26% | 15.08% | 11.54% | 0.75 |
 ELV | 80.15B | 369.07 | 14.69 | 12.62% | 2.62% | 11.92% | 3.96% | 0.75 |
 HUM | 28.76B | 239.53 | 24.34 | 10.06% | 0.82% | 6.17% | 1.3% | 0.73 |
 MCK | 98.11B | 801.01 | 31.14 | 16.22% | 1.09% | 5.33% | ||
 CAH | 46.36B | 197.00 | 30.54 | -1.87% | 0.62% | 3.99% | ||
 LLY | 933.66B | 988.19 | 43.06 | 44.7% | 34.98% | 101.17% | 0.96% | 1.60 |
 PFE | 150.4B | 26.44 | 19.44 | -1.65% | 11.83% | 8.34% | 6.03% | 0.78 |
Compare CVS vs Peers
CVS Health Corporation (CVS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CVS Income Statement
CVS Health Corporation (CVS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 184.79B | 194.58B | 256.78B | 268.71B | 292.11B | 322.47B | 357.78B | 372.81B | 402.07B |
| Revenue Growth % | 4.08% | 5.3% | 31.96% | 4.65% | 8.71% | 10.39% | 10.95% | 4.2% | 7.85% |
| Medical Costs & Claims | 156.26B | 163.04B | 211.25B | 219.66B | 239.99B | 267.96B | 303.35B | 321.41B | 346.7B |
| Medical Cost Ratio % | 84.56% | 83.79% | 82.27% | 81.75% | 82.16% | 83.1% | 84.79% | 86.21% | 86.23% |
| Gross Profit | 28.53B▲ 0% | 31.54B▲ 10.6% | 45.53B▲ 44.4% | 49.05B▲ 7.7% | 52.12B▲ 6.3% | 54.5B▲ 4.6% | 54.43B▼ 0.1% | 51.4B▼ 5.6% | 55.36B▲ 7.7% |
| Gross Margin % | 15.44% | 16.21% | 17.73% | 18.25% | 17.84% | 16.9% | 15.21% | 13.79% | 13.77% |
| Gross Profit Growth % | -1.06% | 10.55% | 44.36% | 7.73% | 6.27% | 4.57% | -0.13% | -5.57% | 7.71% |
| Operating Expenses | 18.99B | 27.52B | 33.54B | 35.13B | 38.81B | 46.55B | 40.69B | 42.88B | 44.98B |
| OpEx / Revenue % | 10.28% | 14.14% | 13.06% | 13.08% | 13.29% | 14.43% | 11.37% | 11.5% | 11.19% |
| Depreciation & Amortization | 2.48B | 2.72B | 4.37B | 4.44B | 4.49B | 4.22B | 4.37B | 4.6B | 4.61B |
| Combined Ratio % | 94.84% | 97.93% | 95.33% | 94.82% | 95.44% | 97.53% | 96.16% | 97.72% | 97.42% |
| Operating Income | 9.54B▲ 0% | 4.02B▼ 57.8% | 11.99B▲ 198.1% | 13.91B▲ 16.1% | 13.31B▼ 4.3% | 7.95B▼ 40.2% | 13.74B▲ 72.8% | 8.52B▼ 38.0% | 10.38B▲ 21.9% |
| Operating Margin % | 5.16% | 2.07% | 4.67% | 5.18% | 4.56% | 2.47% | 3.84% | 2.28% | 2.58% |
| Operating Income Growth % | -8.16% | -57.84% | 198.11% | 16.05% | -4.32% | -40.24% | 72.78% | -38.03% | 21.95% |
| EBITDA | 12.02B | 6.74B | 16.36B | 18.35B | 17.8B | 12.18B | 18.11B | 13.11B | 14.99B |
| EBITDA Margin % | 6.5% | 3.46% | 6.37% | 6.83% | 6.09% | 3.78% | 5.06% | 3.52% | 3.73% |
| Interest Expense | 1.06B | 2.62B | 3.04B | 2.91B | 2.5B | 2.29B | 2.66B | 2.96B | 3.12B |
| Non-Operating Income | 208M | -4M | -45M | 1.23B | 270M | -169M | -88M | -590M | 5.13B |
| Pretax Income | 8.27B▲ 0% | 1.41B▼ 83.0% | 9B▲ 539.9% | 9.77B▲ 8.6% | 10.54B▲ 7.9% | 5.84B▼ 44.6% | 11.17B▲ 91.4% | 6.15B▼ 45.0% | 2.14B▼ 65.3% |
| Pretax Margin % | 4.47% | 0.72% | 3.5% | 3.64% | 3.61% | 1.81% | 3.12% | 1.65% | 0.53% |
| Income Tax | 1.64B | 2B | 2.37B | 2.57B | 2.55B | 1.51B | 2.81B | 1.56B | 408M |
| Effective Tax Rate % | 19.8% | 142.39% | 26.3% | 26.29% | 24.18% | 25.86% | 25.11% | 25.41% | 19.1% |
| Net Income | 6.62B▲ 0% | -594M▼ 109.0% | 6.63B▲ 1216.8% | 7.18B▲ 8.2% | 8B▲ 11.5% | 4.31B▼ 46.1% | 8.34B▲ 93.6% | 4.61B▼ 44.7% | 1.77B▼ 61.7% |
| Net Margin % | 3.58% | -0.31% | 2.58% | 2.67% | 2.74% | 1.34% | 2.33% | 1.24% | 0.44% |
| Net Income Growth % | 24.54% | -108.97% | 1216.84% | 8.22% | 11.45% | -46.12% | 93.55% | -44.7% | -61.68% |
| EPS (Diluted) | 6.44▲ 0% | -0.57▼ 108.9% | 5.08▲ 991.2% | 5.46▲ 7.5% | 5.95▲ 9.0% | 3.26▼ 45.2% | 6.47▲ 98.5% | 3.66▼ 43.4% | 1.39▼ 62.0% |
| EPS Growth % | 31.43% | -108.85% | 991.23% | 7.48% | 8.97% | -45.21% | 98.47% | -43.43% | -62.02% |
| EPS (Basic) | 6.47 | -0.57 | 5.10 | 5.48 | 6.00 | 3.29 | 6.49 | 3.66 | 1.40 |
| Diluted Shares Outstanding | 1.02B | 1.04B | 1.3B | 1.31B | 1.33B | 1.32B | 1.29B | 1.26B | 1.27B |
CVS Balance Sheet
CVS Health Corporation (CVS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 95.13B | 196.46B | 222.45B | 230.72B | 233B | 228.28B | 249.73B | 253.22B | 261.06B |
| Asset Growth % | 0.71% | 106.51% | 13.23% | 3.72% | 0.99% | -2.03% | 9.4% | 1.4% | 3.1% |
| Total Investment Assets | 223M | 18.25B | 19.69B | 23.81B | 26.14B | 23.87B | 26.28B | 31.34B | 35.01B |
| Long-Term Investments | 112M | 15.73B | 17.31B | 20.81B | 23.02B | 21.1B | 23.02B | 28.93B | 32.87B |
| Short-Term Investments | 111M | 2.52B | 2.37B | 3B | 3.12B | 2.78B | 3.26B | 2.41B | 2.15B |
| Total Current Assets | 31.23B | 45.24B | 50.3B | 56.37B | 60.01B | 65.63B | 67.86B | 68.64B | 74.71B |
| Cash & Equivalents | 1.7B | 4.06B | 5.68B | 7.85B | 9.41B | 12.95B | 8.2B | 8.59B | 8.51B |
| Receivables | 13.18B | 17.63B | 19.62B | 21.74B | 24.43B | 27.28B | 35.23B | 36.47B | 39.78B |
| Other Current Assets | 945M | 4.58B | 5.11B | 5.28B | 5.29B | 3.54B | 3.15B | 3.08B | 5.03B |
| Goodwill & Intangibles | 52.08B | 115.2B | 112.87B | 110.69B | 108.15B | 102.95B | 120.51B | 118.59B | 110.99B |
| Goodwill | 38.45B | 78.68B | 79.75B | 79.55B | 79.12B | 78.15B | 91.27B | 91.27B | 85.48B |
| Intangible Assets | 13.63B | 36.52B | 33.12B | 31.14B | 29.03B | 24.8B | 29.23B | 27.32B | 25.51B |
| PP&E (Net) | 10.29B | 11.35B | 32.9B | 33.34B | 32.02B | 30.75B | 30.43B | 28.94B | 28.06B |
| Other Assets | 1.42B | 8.93B | 9.06B | 9.51B | 9.8B | 7.85B | 7.91B | 8.1B | 6.91B |
| Total Liabilities | 57.44B | 137.91B | 158.28B | 161.01B | 157.62B | 156.51B | 173.09B | 177.49B | 185.68B |
| Total Debt | 27B | 73.43B | 89B | 85.04B | 76B | 70.73B | 79.39B | 82.92B | 93.59B |
| Net Debt | 25.31B | 69.37B | 83.32B | 77.19B | 66.59B | 57.79B | 71.19B | 74.33B | 85.08B |
| Long-Term Debt | 22.18B | 71.44B | 64.7B | 59.21B | 51.97B | 50.48B | 58.64B | 60.53B | 72.88B |
| Short-Term Debt | 4.82B | 1.99B | 3.78B | 5.44B | 4.21B | 1.78B | 2.97B | 5.74B | 5.8B |
| Total Current Liabilities | 30.65B | 44.01B | 53.3B | 62.02B | 67.81B | 69.42B | 79.19B | 84.61B | 88.69B |
| Accounts Payable | 8.86B | 8.93B | 10.49B | 11.14B | 12.54B | 14.84B | 14.9B | 15.89B | 59.38B |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 62M |
| Other Current Liabilities | 23M | 4.88B | 4.82B | 5.83B | 5.6B | 2.82B | 2.47B | 1.18B | 23.42B |
| Deferred Taxes | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Liabilities | 1.61B | 14.78B | 14.06B | 14.24B | 13.39B | 15.79B | 14.92B | 13.64B | -2.16B |
| Total Equity | 37.7B▲ 0% | 58.54B▲ 55.3% | 64.17B▲ 9.6% | 69.7B▲ 8.6% | 75.38B▲ 8.1% | 71.77B▼ 4.8% | 76.64B▲ 6.8% | 75.73B▼ 1.2% | 75.38B▼ 0.5% |
| Equity Growth % | 2.34% | 55.31% | 9.61% | 8.62% | 8.15% | -4.79% | 6.78% | -1.18% | -0.46% |
| Shareholders Equity | 37.69B | 58.23B | 63.86B | 69.39B | 75.08B | 71.47B | 76.46B | 75.56B | 75.21B |
| Minority Interest | 4M | 318M | 306M | 312M | 306M | 300M | 175M | 170M | 168M |
| Retained Earnings | 43.56B | 40.91B | 45.11B | 49.64B | 54.91B | 56.4B | 61.6B | 62.84B | 61.2B |
| Common Stock | 32.1B | 45.44B | 45.97B | 46.51B | 47.38B | 48.19B | 48.99B | 18M | 18M |
| Accumulated OCI | -165M | 102M | 1.02B | 1.41B | 965M | -1.26B | -297M | -120M | 406M |
| Return on Equity (ROE) | 17.77% | -1.23% | 10.81% | 10.73% | 11.03% | 5.86% | 11.24% | 6.06% | 2.34% |
| Return on Assets (ROA) | 6.99% | -0.41% | 3.17% | 3.17% | 3.45% | 1.87% | 3.49% | 1.83% | 0.69% |
| Equity / Assets | 39.62% | 29.8% | 28.85% | 30.21% | 32.35% | 31.44% | 30.69% | 29.91% | 28.87% |
| Debt / Equity | 0.72x | 1.25x | 1.39x | 1.22x | 1.01x | 0.99x | 1.04x | 1.09x | 1.24x |
| Book Value per Share | 36.81 | 56.08 | 49.17 | 53.04 | 56.72 | 54.25 | 59.41 | 60.01 | 59.31 |
| Tangible BV per Share | -14.05 | -54.27 | -37.32 | -31.20 | -24.65 | -23.57 | -34.01 | -33.97 | -28.01 |
CVS Cash Flow Statement
CVS Health Corporation (CVS) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 8.01B | 8.87B | 12.85B | 15.87B | 18.27B | 16.18B | 13.43B | 9.11B | 10.64B |
| Operating CF Growth % | -21.04% | 10.72% | 44.93% | 23.48% | 15.13% | -11.43% | -17.01% | -32.17% | 16.82% |
| Operating CF / Revenue % | 4.33% | 4.56% | 5% | 5.9% | 6.25% | 5.02% | 3.75% | 2.44% | 2.65% |
| Net Income | 6.62B | -596M | 6.63B | 7.19B | 7.99B | 4.33B | 8.37B | 4.59B | 1.77B |
| Depreciation & Amortization | 2.48B | 2.72B | 4.37B | 4.44B | 4.49B | 4.22B | 4.37B | 4.6B | 0 |
| Stock-Based Compensation | 234M | 280M | 453M | 400M | 484M | 447M | 588M | 540M | 0 |
| Deferred Taxes | -1.33B | 87M | -654M | -570M | -402M | -2.03B | -676M | -572M | 0 |
| Other Non-Cash Items | 421M | 6.49B | 548M | 1.24B | 1.85B | 2.39B | 765M | -153M | 10.35B |
| Working Capital Changes | -416M | -112M | 1.5B | 3.16B | 3.86B | 6.82B | 15M | 109M | -1.47B |
| Cash from Investing | -2.88B | -43.28B | -3.34B | -5.53B | -5.26B | -5.05B | -20.89B | -7.61B | -5.87B |
| Capital Expenditures | -1.92B | -2.04B | -2.46B | -2.44B | -2.52B | -2.73B | -3.03B | -2.78B | -2.83B |
| Acquisitions | -1.18B | -41.39B | -444M | -26M | -146M | -1.39B | -16.61B | -95M | -436M |
| Purchase of Investments | -137M | -692M | -7.53B | -9.64B | -9.96B | -7.75B | -9.04B | -15.19B | -15.01B |
| Sale/Maturity of Investments | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Investing | 298M | 21M | 47M | 101M | 122M | 85M | 68M | 101M | 26M |
| Cash from Financing | -6.75B | 36.82B | -7.65B | -7.7B | -11.36B | -10.52B | 2.68B | -1.14B | -4.94B |
| Dividends Paid | -2.05B | -2.04B | -2.6B | -2.62B | -2.63B | -2.91B | -3.13B | -3.37B | -3.4B |
| Share Repurchases | -4.36B | 0 | 0 | 0 | 0 | -3.5B | -2.01B | -3.02B | 0 |
| Stock Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 394M |
| Debt Issuance (Net) | -1000K | 1000K | -1000K | -1000K | -1000K | -1000K | 1000K | 1000K | -1000K |
| Other Financing | 257M | 592M | 269M | 601M | 536M | 102M | -105M | 202M | 1.96B |
| Net Change in Cash | -1.62B▲ 0% | 2.4B▲ 247.8% | 1.85B▼ 22.5% | 2.63B▲ 42.0% | 1.65B▼ 37.5% | 614M▼ 62.7% | -4.78B▼ 878.5% | 359M▲ 107.5% | -172M▼ 147.9% |
| Exchange Rate Effect | 1000K | -1000K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash at Beginning | 3.52B | 1.9B | 6.55B | 8.41B | 11.04B | 12.69B | 13.3B | 8.53B | 8.88B |
| Cash at End | 1.9B | 4.29B | 8.41B | 11.04B | 12.69B | 13.3B | 8.53B | 8.88B | 8.71B |
| Free Cash Flow | 6.09B▲ 0% | 6.83B▲ 12.1% | 10.39B▲ 52.2% | 13.43B▲ 29.2% | 15.74B▲ 17.3% | 13.45B▼ 14.6% | 10.39B▼ 22.7% | 6.33B▼ 39.1% | 7.81B▲ 23.4% |
| FCF Growth % | -23.09% | 12.14% | 52.18% | 29.23% | 17.26% | -14.58% | -22.71% | -39.14% | 23.41% |
| FCF Margin % | 3.3% | 3.51% | 4.05% | 5% | 5.39% | 4.17% | 2.91% | 1.7% | 1.94% |
| FCF per Share | 5.95 | 6.54 | 7.96 | 10.22 | 11.85 | 10.17 | 8.06 | 5.01 | 6.14 |
CVS Key Ratios
CVS Health Corporation (CVS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Combined Ratio | 94.15% | 94.84% | 97.93% | 95.33% | 94.82% | 95.44% | 97.53% | 96.16% | 97.72% | 97.42% |
| Medical Cost Ratio | 83.76% | 84.56% | 83.79% | 82.27% | 81.75% | 82.16% | 83.1% | 84.79% | 86.21% | 86.23% |
| Return on Equity (ROE) | 14.36% | 17.77% | -1.23% | 10.81% | 10.73% | 11.03% | 5.86% | 11.24% | 6.06% | 2.34% |
| Return on Assets (ROA) | 5.69% | 6.99% | -0.41% | 3.17% | 3.17% | 3.45% | 1.87% | 3.49% | 1.83% | 0.69% |
| Equity / Assets | 38.99% | 39.62% | 29.8% | 28.85% | 30.21% | 32.35% | 31.44% | 30.69% | 29.91% | 28.87% |
| Book Value / Share | 34.14 | 36.81 | 56.08 | 49.17 | 53.04 | 56.72 | 54.25 | 59.41 | 60.01 | 59.31 |
| Debt / Equity | 0.75x | 0.72x | 1.25x | 1.39x | 1.22x | 1.01x | 0.99x | 1.04x | 1.09x | 1.24x |
| Revenue Growth | 15.82% | 4.08% | 5.3% | 31.96% | 4.65% | 8.71% | 10.39% | 10.95% | 4.2% | 7.85% |
CVS SEC Filings & Documents
CVS Health Corporation (CVS) SEC filings — annual & quarterly reports (10-K, 10-Q)
CVS Frequently Asked Questions
CVS Health Corporation (CVS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
CVS Health Corporation (CVS) grew revenue by 7.8% over the past year. This is steady growth.
Yes, CVS Health Corporation (CVS) is profitable, generating $1.77B in net income for fiscal year 2025 (0.4% net margin).
Dividend & Returns
Yes, CVS Health Corporation (CVS) pays a dividend with a yield of 3.31%. This makes it attractive for income-focused investors.
CVS Health Corporation (CVS) has a return on equity (ROE) of 2.3%. This is below average, suggesting room for improvement.
Industry Metrics
CVS Health Corporation (CVS) has a combined ratio of 97.4%. A ratio below 100% indicates underwriting profitability.
Explore More CVS
CVS Health Corporation (CVS) financial analysis — history, returns, DCA and operating performance tools
Full CVS Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates